Latest Conference Coverage

Clinical Research in ALS, the Potential of CNM-Au8 in the Care Landscape: James Berry, MD, MPH

The director of the Massachusetts General Hospital ALS Care Center discussed the importance of effective disease-modifying therapies for ALS and the potential of CNM-Au8 in the management of the disease. [WATCH TIME: 2 minutes]

Pridopidine Shows Clinically Meaningful Results in Huntington Disease for Patients Not on Neuroleptics, Chorea Medications

Q-Motor, an objective measure of motor function, showed robust beneficial effects for individuals treated with pridopidine in PROOF-HD at various time points.

Imad Najm, MD, on the World Brain Study After 1 Year

The director of Cleveland Clinic's Epilepsy Center at the Cleveland Clinic Neurological Institute shared his insight into the findings of the World Brain Study, 15 months after its initiation.

Serum Ravulizumab Concentrations Maintained Above Therapeutic Threshold in AQP4+ NMOSD

Inhibition of serum free complement 5 with ravulizumab was sustained throughout the treatment period according to a pharmacokinetics and pharmacodynamics analysis.

EEG as a Diagnostic Tool for Mild Cognitive Impairment: Andrew Budson, MD

The professor of neurology at Boston University Chobanian & Avedisian School of Medicine talked about diagnostic tools and using memory aids for patients with cognitive impairment at the 2023 AAN Annual Meeting. [WATCH TIME: 7 minutes]

Leriglitazone Demonstrates Lesion Growth Deceleration in Pediatric Cerebral Adrenoleukodystrophy

Minoryx's leriglitazone showed a decrease in matrix metalloproteinase-9 concentrations in pediatric patients with cerebral adrenoleukodystrophy, according to a 24-week analysis.

Postictal Generalized EEG Suppression as a Biomarker for SUDEP: Nancy R. Foldvary-Schaefer, DO, FAAN

The director of the Sleep Disorders Center and staff in the Epilepsy Center at Cleveland Clinic discussed how additional sensors in seizure monitoring for patients with epilepsy may help better manage the risk of SUDEP. [WATCH TIME: 3 minutes]

Remaining Questions and Next Steps for Parkinson Agent P2B001: Lawrence Elmer, MD, PhD; Cheryl Fitzer-Attas, PhD

The medical director of the Center for Neurological Disorders at the University of Toledo discussed positive phase 3 findings assessing P2B001, and how the agent would potentially fit in the Parkinson treatment landscape. [WATCH TIME: 4 minutes]

Phase 3 NEURO-TTRansform Findings Signify Eplontersen as Promising Agent for hATTR Polyneuropathy

After 66 weeks of treatment, patients on eplontersen showed sustained reduction in TTR concentration, halted progression of neuropathy impairment, and improved quality of life.

Understanding Reasons for Greater Disability, Loss of Deep Gray Matter in Latinx Patients With MS: Daniel Ontaneda, MD, PhD

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine of Case Western University discussed a presentation at AAN 2023 characterizing the clinical and MRI features of Latinx with multiple sclerosis. [WATCH TIME: 4 minutes]

Phase 3 PROGRESS Results Highlight Atogepant’s Benefit in Chronic Migraine

In comparison with placebo, atogepant 30 mg twice daily and 60 mg once daily resulted in greater reductions in monthly migraine days, as well as proportion of patients with at least 50% reduction in 3-month average of MMDs.

Todd Levine, MD, on the Syn-One Test and Its Role in Neurodgenerative Disorder Diagnosis

The chief medical officer and cofounder of CND Life Sciences, who served as principal investigator of the study, offered insight into the Syn-ONe Test's clinical utility.

Oral Levodopa/Carbidopa Pump May Improve ON/OFF Time in Parkinson Disease

The pump, attached to a wearable retainer, continuously delivers the liquid medication with little to no adverse effects.

Ravulizumab Superior in Preventing On-Trial Relapse in Subgroups of NMOSD

The treatment was superior in preventing on-trial relapse in both the monotherapy and immunosuppressive therapy groups compared with placebo in the CHAMPION-NMOSD trial.

Impressive Response Rates for Patients in Migraine Prevention Study: Peter J. Goadsby, MD, PhD, DSc

The professor of neurology at King’s College, London, spoke about the phase 3 ELEVATE trial investigating atogepant for episodic migraine at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

Effectiveness of Minimally Invasive Parafascicular Surgery in Intracerebral Hemorrhage: Andrew Russman, DO

The head of the Stroke Program and Medical Director of the Comprehensive Stroke Center at Cleveland Clinic provided perspective on the ENRICH trial, the first positive surgical trial for intracerebral hemorrhage. [WATCH TIME: 5 minutes]

Syn-One Test Reports High Sensitivity and Specificity Across Multiple Synucleinopathies

CND Life Sciences’ α-synuclein skin biopsy test showed sensitivity rates ranging from 92.7% to 100% across a number of assessed and clinically confirmed synucleinopathies, including Parkinson disease and dementia with Lewy bodies, among others.

Common Migraine Prodromal Symptoms Improved Through Acute Ubrogepant

A greater proportion of patients on ubrogepant reported absence of moderate-to-severe intensity headache within 48 hours, ability to function normally, and absence of headache of any intensity.

Early Progress From the World Brain Study: Imad Najm, MD

The director of Cleveland Clinic’s Epilepsy Center provided an update on the World Brain Study, a large-scale, longitudinal study aimed to observe the early, underlying changes in neurological disorders. [WATCH TIME: 9 minutes]

NeuroVoices: John Greenfield, MD, PhD, on the Growth of Neurology and the Budding Young Community of Neurologists

The president elect of the Association of University Professors of Neurology provided thoughts on the promising concepts in neurology and the reasons young medical professionals should join the field.

ALS Agent SAR443820 Shows High CNS Penetration, Promising Safety Profile in Phase 1 Study

In single-ascending dose and multiple-ascending dose studies, no clinically meaningful changes were noted in hematology, chemistry, vital signs, or electrocardiogram parameters.

Cell Therapy NRTX-1001 Posts Positive Preliminary Data in Drug-Resistant Mesial Temporal Lobe Epilepsy

Neurona Therapeutics’ single-administration allogeneic cell therapy suggests thus far that the treatment is safe, with signs of efficacy, after reading out data from the first 2 patients dosed.

Improving Diagnosis, Screening Patients More Efficiently in Alzheimer Disease: Katherine Turk, MD

The behavioral neurologist at VA Boston Healthcare System talked about screening patients for mild cognitive impairment to improve diagnosis in Alzheimer disease at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

Disease Activity in Early-Stage Relapsing MS Remains Minimal After 4 Years of Ocrelizumab Treatment

After 192 weeks, more than 90% of patients on ocrelizumab had no relapses and slightly more than 80% had no 24-week confirmed disability progression.

Results of Clinical Trials for CNM-Au8, A Potential ALS Treatment: James Berry, MD, MPH

The director of the Massachusetts General Hospital ALS Care Center talked about CNM-Au8 treatment across three populations, as well as the HEALEY ALS Platform Trial, at the 2023 AAN annual meeting. [WATCH TIME: 5 minutes]

Ocrelizumab Showed No Evidence of Disease Activity in Early-Remitting MS

Higher rates of no evidence of disease activity and no 24-week confirmed disability progression or relapses were observed in patients that continued with ocrelizumab.

Accuracy of DCTclock to Detect Cognitive Impairment: Ali Jannati, MD, PhD

The manager of Clinical Development-Research at Linus Health provided perspective on 2 analyses presented at the 2023 AAN Annual Meeting on the reliability of the DCTclock to detect cognitive impairment. [WATCH TIME: 4 minutes]

Low Dose Combination of Extended-Release Pramipexole and Rasagiline Shows Comparable Efficacy to Pramipexole Alone, With Greater Safety

No significant differences between P2B001 and Prami-ER were seen in total UPDRS responders, UPDRS Part II, and UPDRS Part III scores among those with Parkinson disease.

Development of Neuropathology Targeted Treatments in Alzheimer Disease: Madhav R. Thambisetty, MD, PhD

The senior investigator at the National Institute on Aging talked about targeting pathologies in neurodegenerative diseases at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

Higher Rates of Adverse Events, Discontinuations in Optimization Phase of Continuous Fosvelodopa/Foscarbidopa

Adverse events like dyskinesia, ON and OFF phenomenon, and falls, were all higher during the 4-week optimization phase than the 8-week maintenance phase.